Active, not recruitingPHASE1, PHASE2NCT02797470
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AIDS Malignancy Consortium
- Principal Investigator
- Mehrdad AbediAIDS Malignancy Consortium
- Intervention
- Autologous Hematopoietic Stem Cell Transplantation(procedure)
- Enrollment
- 11 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2036
Study locations (4)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Collaborators
National Cancer Institute (NCI) · California Institute for Regenerative Medicine (CIRM)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02797470 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital